Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 12 studies | 25% ± 8% | |
lung | 9 studies | 21% ± 5% | |
brain | 5 studies | 32% ± 12% | |
intestine | 4 studies | 20% ± 5% | |
heart | 4 studies | 21% ± 2% | |
adipose | 4 studies | 19% ± 2% | |
pancreas | 3 studies | 35% ± 14% | |
eye | 3 studies | 28% ± 8% | |
uterus | 3 studies | 25% ± 7% | |
liver | 3 studies | 23% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 10439.03 | 1445 / 1445 | 100% | 43.16 | 183 / 183 |
liver | 100% | 4226.21 | 226 / 226 | 100% | 35.00 | 406 / 406 |
prostate | 100% | 7318.68 | 245 / 245 | 100% | 41.78 | 502 / 502 |
stomach | 100% | 7260.99 | 359 / 359 | 100% | 42.00 | 286 / 286 |
lung | 100% | 11270.38 | 578 / 578 | 100% | 39.93 | 1154 / 1155 |
breast | 100% | 12245.99 | 459 / 459 | 100% | 58.93 | 1116 / 1118 |
bladder | 100% | 9496.90 | 21 / 21 | 100% | 37.52 | 503 / 504 |
intestine | 100% | 9403.62 | 966 / 966 | 100% | 39.67 | 525 / 527 |
kidney | 100% | 5865.81 | 89 / 89 | 100% | 47.38 | 897 / 901 |
thymus | 100% | 8556.51 | 652 / 653 | 100% | 38.63 | 602 / 605 |
uterus | 100% | 9223.13 | 170 / 170 | 99% | 38.52 | 456 / 459 |
skin | 100% | 8067.19 | 1809 / 1809 | 98% | 31.99 | 464 / 472 |
ovary | 100% | 8470.53 | 180 / 180 | 98% | 19.09 | 422 / 430 |
adrenal gland | 100% | 6857.66 | 258 / 258 | 97% | 27.51 | 224 / 230 |
brain | 95% | 3332.34 | 2508 / 2642 | 100% | 42.02 | 704 / 705 |
pancreas | 95% | 3333.04 | 312 / 328 | 99% | 44.50 | 177 / 178 |
adipose | 100% | 13597.70 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 11901.97 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.47 | 29 / 29 |
muscle | 100% | 10222.92 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7863.65 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 39.40 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.82 | 1 / 1 |
heart | 99% | 10334.09 | 854 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 5061.99 | 901 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 20.98 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016032 | Biological process | viral process |
GO_0098792 | Biological process | xenophagy |
GO_1901098 | Biological process | positive regulation of autophagosome maturation |
GO_0034341 | Biological process | response to type II interferon |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0000421 | Cellular component | autophagosome membrane |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0016605 | Cellular component | PML body |
GO_0005776 | Cellular component | autophagosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | CALCOCO2 |
Protein name | Calcium-binding and coiled-coil domain-containing protein 2 (Nuclear domain 10 protein NDP52) Calcium binding and coiled-coil domain 2 Calcium-binding and coiled-coil domain-containing protein 2 (Antigen nuclear dot 52 kDa protein) (Nuclear domain 10 protein NDP52) (Nuclear domain 10 protein 52) (Nuclear dot protein 52) |
Synonyms | NDP52 |
Description | FUNCTION: Xenophagy-specific receptor required for autophagy-mediated intracellular bacteria degradation. Acts as an effector protein of galectin-sensed membrane damage that restricts the proliferation of infecting pathogens such as Salmonella typhimurium upon entry into the cytosol by targeting LGALS8-associated bacteria for autophagy . Initially orchestrates bacteria targeting to autophagosomes and subsequently ensures pathogen degradation by regulating pathogen-containing autophagosome maturation . Bacteria targeting to autophagosomes relies on its interaction with MAP1LC3A, MAP1LC3B and/or GABARAPL2, whereas regulation of pathogen-containing autophagosome maturation requires the interaction with MAP3LC3C . May play a role in ruffle formation and actin cytoskeleton organization and seems to negatively regulate constitutive secretion . . |
Accessions | ENST00000448105.6 [Q13137-4] ENST00000509415.5 ENST00000416445.6 [Q13137-2] ENST00000509784.1 H0Y9G3 D6RBI4 D6RF70 Q13137 ENST00000509507.5 [Q13137-3] ENST00000513119.5 D6RJE7 I3L493 D6REB0 ENST00000502761.1 ENST00000507306.1 D6RBF9 ENST00000507076.1 ENST00000258947.8 [Q13137-1] ENST00000505071.5 ENST00000508679.5 [Q13137-5] ENST00000570513.5 I3L4E1 ENST00000576582.5 H0YBP4 |